LONDON (Alliance News) - Shares in ANGLE PLC rose 6.7% Monday after it saw positive results using its Parsortix system to analyse Circulating Tumour Cells in the blood of metastatic liver cancer patients.
The test, undertaken by Hari Nageswaran at the University of Surrey's Oncology department, showed that the Parsortix system was able to capture CTCs from blood samples in the patients even though they had undergone surgery to remove their primary tumour and had had chemotherapy.
The study was intended to compare the CTC count from blood samples taken in the peripheral and hepatic liver veins during surgery to remove a section of the liver, in patients who had had a primary cancer removed from the colon and undertaken chemotherapy who had then relapsed with secondary liver cancer.
The study showed that a higher concentration of CTC's were found in the hepatic blood than the peripheral blood, indicating that the concentration of CTC in the blood is higher when in closer proximity to the location of the secondary cancer.
Shares in Angle were trading up 6.7% at 96.01 pence Monday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Angle (AGL)